Otsuka Holdings CoSTU:OS1 +2.63%86 Net Margin % is 15.60% as of Mar. 2026, which is 79% above its 10-year median of 8.72. GuruFocus rates STU:OS1 with a GF Score™ of 86/100 and a GF Value™ of €45.23 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 956 Drug Manufacturers companies, Otsuka Holdings Co ranks better than 78.56% on this metric.
The historical rank and industry rank for Otsuka Holdings Co's Net Margin % or its related term are showing as below:
STU:OS1'
s Net Margin % Range Over the Past 10 Years
Min: 6.02 Med: 8.72 Max: 14.96
Current: 14.96
STU:OS1's Net Margin % is ranked better than 78.56% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:OS1: 14.96
Otsuka Holdings Co (STU:OS1) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Otsuka Holdings Co Net Margin % Related Terms
Otsuka Holdings Co Net Margin % Historical Data
* Premium members only.
The historical data trend for Otsuka Holdings Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OS1 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Otsuka Holdings Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otsuka Holdings Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Otsuka Holdings Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Otsuka Holdings Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otsuka Holdings Co (STU:OS1) has a Net Margin % of 15.60% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Otsuka Holdings Co and its competitors. This is 79% above median its historical median of 8.72. Over the past decade, Otsuka Holdings Co's Net Margin % has ranged from 6.02 to 14.96. According to the industry distribution chart, Otsuka Holdings Co ranks #205 out of 956 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Otsuka Holdings Co's Net Margin % too high?
Otsuka Holdings Co's current Net Margin % of 15.60% is 79% above median its 10-year median of 8.72. Over the past 10 years, this metric has ranged from a low of 6.02 to a high of 14.96. The Drug Manufacturers industry median Net Margin % is 5.56. Otsuka Holdings Co's value of 15.60% is 180.6% above this industry median. Based on the distribution chart, Otsuka Holdings Co ranks #205 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Otsuka Holdings Co has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Otsuka Holdings Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Otsuka Holdings Co ranks #205 out of 956 companies for Net Margin %. This places Otsuka Holdings Co in the top 21% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Otsuka Holdings Co's value of 15.60% is 180.6% above this benchmark. Historically, Otsuka Holdings Co's own Net Margin % has ranged from 6.02 to 14.96 over the past decade. While the company's 10-year median is 8.72 vs. the industry median of 5.56, Otsuka Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otsuka Holdings Co's current Net Margin % of 15.60% is 180.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Otsuka Holdings Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otsuka Holdings Co's current Net Margin % is 15.60%, which is 79% above median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otsuka Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Otsuka Holdings Co (STU:OS1) is currently considered Modestly Overvalued. The stock's GF Value™ is €45.23, compared to a current price of €58.50 — trading 29.3% above its estimated fair value. The current Net Margin % is 15.60%, which is 79% above median its 10-year median of 8.72 and 180.6% above the Drug Manufacturers industry median of 5.56. Otsuka Holdings Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Otsuka Holdings Co (STU:OS1), the current Net Margin % is 15.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Otsuka Holdings Co (STU:OS1) Overvalued in 2026?
Based on GuruFocus' analysis, Otsuka Holdings Co stock appears to be overvalued.
The current stock price of €58.50 is trading 29.3% above its estimated GF Value™ of €45.23.
GuruFocus considers Otsuka Holdings Co to be Modestly Overvalued.
Key valuation signals for STU:OS1:
Net Margin %: 15.60% (79% above median its 10-year median of 8.72)
GF Value™: €45.23 vs. price of €58.50 (29.3% above fair value)
Industry Position: 180.6% above the Drug Manufacturers median (#205 of 956)
No single metric tells the full story. See the STU:OS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Otsuka Holdings Co Ltd is a Japan-based company that operates in pharmaceuticals, nutraceuticals, and consumer products. It operates through four reportable segments: Medical-related Business, Nutraceutical-related Business, Consumer-related Business, and Other Business. The Medical Business manufactures and sells therapeutic drugs and infusions, the Nutraceutical Business produces functional foods, beverages, and nutritional supplements, the Consumer Business offers mineral water, beverages, and foods, while the Other Business provides storage services and manufactures chemicals and analytical equipment. It generates the majority of its revenue from the medical-related business segment.
86GF Score
Get the complete analysis for STU:OS1
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OS1 has been successfully added to your 
